Biomarkers of response to angiogenesis inhibitors: An open and unsolved question

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 6-8

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CD133 ANTIGEN; CELECOXIB; CM 101; CYCLOPHOSPHAMIDE; CYTOKINE; ENDOSTATIN; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; INTERLEUKIN 8; METHOTREXATE; PROTEOME; SCATTER FACTOR; SEMAXANIB; SUNITINIB; THROMBOCYTE FACTOR 4; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD LEVEL; CANCER INHIBITION; CELL COUNT; CELL VIABILITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; HUMAN; METASTASIS; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; URINE LEVEL;

EID: 71249097473     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.022     Document Type: Note

References (29)

1. Nico B., Benagiano V., Mangieri D., et al. Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol 23 (2008) 691-697
2. Martin-Padura I., and Bertolini F. Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Front Biosci 1 (2009) 304-318
3. Cervi D., Yip T.T., Bhattacharya N., et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111 (2008) 1201-1207
4. Kumar H., Heer K., Greenman J., Kerin M.J., and Monson J.R. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 22 (2002) 1877-1880
5. Norden-Zfoni A., Desai J., Manola J., et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 2643-2650
6. Byrne G.J., Ghellal A., Iddon J., et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 92 (2000) 1329-1336
7. Herbst R.S., Hess K.R., Tran H.T., et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20 (2002) 3792-3803
8. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16 (2005) 558-565
9. Kuenen B.C., Levi M., Meijers J.C., et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Clin Oncol 21 (2003) 2192-2198
10. Dowlati A., Robertson K., Radivoyevitch T., et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 11 (2005) 7938-7944
11. DeVore R.F., Hellerqvist C.G., Wakefield G.B., et al. Phase I study of the antineovascularization drug CM101. Clin Cancer Res 3 (1997) 365-372
12. Stempak D., Gammon J., Halton J., et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 28 (2006) 720-728
13. Dobrucki L.W., and Sinusas A.J. Imaging angiogenesis. Curr Opin Biotech 18 (2007) 1-7
14. Mulder W.J., van der Schaft D.W., Hautvast P.A., et al. Early in vivo assessment of angiostatic therapy afficacy by molecular MRI. FASEB J 21 (2007) 378-383
15. Klibanov A.L. Ligand-carrying gas-filled microbubbles: ultrasound agents for targeted molecular imaging. Bioconjug Chem 16 (2005) 9-17
16. Mancuso P., Burlini A., Pruneri G., et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97 (2001) 3658-3661
17. Zhang H., Vakil V., Braunstein M., et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105 (2005) 3286-3294
18. Fürstenberger G., von Moos R., Lucas R., et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94 (2006) 524-531
19. Mancuso P., Colleoni M., Calleri A., et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108 (2006) 452-459
20. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
21. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haemopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat Rev Cancer 2 (2002) 826-835
22. Monestiroli S., Mancuso P., Burlini A., et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 61 (2001) 4341-4344
23. Capillo M., Mancuso P., Gobbi A., et al. Continuous infusion of endostatin inhibits differentiation, mobilization and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9 (2003) 377-382
24. Taylor M., Rössler J., Geoerger B., et al. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 15 (2009) 4561-4571
25. Vroling L., van der Veldt A.A., de Haas R.R., et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 12 (2009) 69-79
26. Greenfield J.P., Jin D.K., Young L.M., et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 64 (2009) 819-826
27. Rabascio C., Muratori E., Mancuso P., et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 64 (2004) 4373-4377
28. Mehra N., Penning M., Maas J., et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 12 (2006) 4859-4866
29. Lin E.H., Hassan M., Li Y., et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110 (2007) 534-542